Synthesis, Molecular Modeling, Anti-Cancer and COX-1/2 Inhibitory Activities of Novel Thiazolidinones Containing Benzothiazole Core

dc.contributor.author Kulabas, Necla
dc.contributor.author Guven, Cansu Tamniku
dc.contributor.author Duracık, Merve
dc.contributor.author Bingol Ozakpinar, Ozlem
dc.contributor.author Küçükgüzel, İlkay
dc.date.accessioned 2025-10-10T16:06:29Z
dc.date.available 2025-10-10T16:06:29Z
dc.date.issued 2024
dc.description.abstract In this study, new 1,3-thiazolidin-4-one derivatives containing arylmethylene groups in the 5-position were obtained from 6-(trifluoromethoxy)-1,3-benzo-thiazol-2-amine (riluzole). Synthesized compounds were characterized by spectral data and elemental analysis. In vitro, cytotoxic activities of the synthesized molecules were evaluated against the human lung cancer (A549) and human prostate cancer (PC-3) cell lines. Compounds were also tested on mouse embryonic fibroblast cells (NIH/3T3) to determine selectivity. Ten target compounds 3-12 were also screened for their COX-1 and COX-2 inhibitory activities. Of these compounds, 4 showed the highest COX-2 inhibition at 10 μM. Molecular docking calculations were performed to understand the binding interactions of compounds with COX-1 and COX-2 proteins. In silico studies of the tested compounds represented important binding modes that may be responsible for their anti-cancer activity via selective inhibition of the COX-2 enzyme. ADMET predictions were conducted to assess the drug-like properties of the novel compounds. © 2024 Elsevier B.V., All rights reserved. en_US
dc.identifier.doi 10.3329/bjp.v19i1.70297
dc.identifier.issn 1991-0088
dc.identifier.scopus 2-s2.0-85188348663
dc.identifier.uri https://doi.org/10.3329/bjp.v19i1.70297
dc.identifier.uri https://hdl.handle.net/20.500.14627/1192
dc.language.iso en en_US
dc.publisher Bangladesh Pharmacological Society en_US
dc.relation.ispartof Bangladesh Journal of Pharmacology en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Benzothiazole en_US
dc.subject Riluzole en_US
dc.subject 1,3-Thiazolidin-4-One Derivative en_US
dc.subject 2-Chloro-N-[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Acetamide en_US
dc.subject 2-Heteroarylimino-5-Arylmethylene-1,3-Thiazolidin-4-One Derivative en_US
dc.subject 2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 4-Thiazolidinone Derivative en_US
dc.subject 5-(2-Chlorobenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(2-Fluorobenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(2-Methoxybenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(3-Chlorobenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(3-Fluorobenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(3-Methoxybenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(4-Chlorobenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(4-Fluorobenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(4-Methoxybenzylidene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject 5-(Substituted Aryl Methylene)-2-[[6-(Trifluoromethoxy)-1,3-Benzothiazol-2-yl]Imino]-1,3-Thiazolidin-4-One en_US
dc.subject Benzothiazole en_US
dc.subject Cyclooxygenase 1 en_US
dc.subject Cyclooxygenase 2 en_US
dc.subject Riluzole en_US
dc.subject Unclassified Drug en_US
dc.subject A-549 Cell Line en_US
dc.subject Animal Cell en_US
dc.subject Antineoplastic Activity en_US
dc.subject Article en_US
dc.subject Cell Culture en_US
dc.subject Computer Model en_US
dc.subject Controlled Study en_US
dc.subject Cytotoxicity en_US
dc.subject Drug Adsorption en_US
dc.subject Drug Distribution en_US
dc.subject Drug Effect en_US
dc.subject Drug Excretion en_US
dc.subject Drug Metabolism en_US
dc.subject Drug Screening en_US
dc.subject Drug Selectivity en_US
dc.subject Drug Structure en_US
dc.subject Drug Synthesis en_US
dc.subject Elemental Analysis en_US
dc.subject Enzyme Activity en_US
dc.subject Enzyme Inhibition en_US
dc.subject Human en_US
dc.subject Human Cell en_US
dc.subject In Vitro Study en_US
dc.subject Molecular Docking en_US
dc.subject Molecular Model en_US
dc.subject Mouse en_US
dc.subject NIH 3T3 Cell Line en_US
dc.subject Nonhuman en_US
dc.subject PC-3 [Human Prostate Carcinoma] Cell Line en_US
dc.subject Protein-Protein Interaction en_US
dc.title Synthesis, Molecular Modeling, Anti-Cancer and COX-1/2 Inhibitory Activities of Novel Thiazolidinones Containing Benzothiazole Core en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.scopusid 57190582389
gdc.author.scopusid 58949515100
gdc.author.scopusid 57218628581
gdc.author.scopusid 39161700400
gdc.author.scopusid 6603485785
gdc.description.department Fenerbahçe University en_US
gdc.description.departmenttemp [Kulabas] Necla, Department of Pharmaceutical Technology Faculty of Pharmacy, Marmara Üniversitesi, Istanbul, Turkey; [Guven] Cansu Tamniku, Department of Pharmaceutical Chemistry, Marmara Üniversitesi, Istanbul, Turkey; [Duracık] Merve, Department of Biochemistry, Marmara Üniversitesi, Istanbul, Turkey; [Bingol Ozakpinar] Ozlem, Department of Biochemistry, Marmara Üniversitesi, Istanbul, Turkey; [Küçükgüzel] İlkay, Department of Pharmaceutical Chemistry, Fenerbahçe University, Istanbul, Turkey en_US
gdc.description.endpage 12 en_US
gdc.description.issue 1 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q4
gdc.description.startpage 1 en_US
gdc.description.volume 19 en_US
gdc.description.wosquality Q4

Files